Scholarlink

Purpose of Review <p>Effective heart failure (HF) management requires timely recognition and treatment of congestion in both inpatient and outpatient settings. As the complexity of HF care increases, there is a growing interest in improved guided therapy strategies, including both biomarker-driven approaches and non-invasive and invasive remote monitoring. </p> Recent Findings <p>While natriuretic peptides remain the cornerstone of biomarker-based prognostication, emerging biomarkers reflecting diverse pathophysiological processes, such as myocardial stress, fibrosis, and inflammation, offer potential for enhanced risk stratification, particularly when used in serial multimarker panels. Despite their prognostic value, biomarkers are not yet routinely employed in guided therapy. Additionally with the increasing availability hemodynamic remote monitoring strategies and devices, we could learn more about pathophysiological processes, multi-biomarker panels and their relation to congestion and risks for progression of HF which can help to further refine biomarker-guided therapy.</p> Summary <p>This review evaluates the potential use of biomarkers in guided therapy for HF and explores the rationale for their integration into multimodal monitoring frameworks aiming for a more personalized and dynamic model of HF care, in which different monitoring approaches can reinforce each other.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Toward Personalized Heart Failure Management: Integrating Biomarkers and Multimodal Monitoring Strategies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月4日

查看全文
  • Youssra Allach,
  • Mylène Barry - Loncq de Jong,
  • Jasper J. Brugts

摘要

Purpose of Review

Effective heart failure (HF) management requires timely recognition and treatment of congestion in both inpatient and outpatient settings. As the complexity of HF care increases, there is a growing interest in improved guided therapy strategies, including both biomarker-driven approaches and non-invasive and invasive remote monitoring.

Recent Findings

While natriuretic peptides remain the cornerstone of biomarker-based prognostication, emerging biomarkers reflecting diverse pathophysiological processes, such as myocardial stress, fibrosis, and inflammation, offer potential for enhanced risk stratification, particularly when used in serial multimarker panels. Despite their prognostic value, biomarkers are not yet routinely employed in guided therapy. Additionally with the increasing availability hemodynamic remote monitoring strategies and devices, we could learn more about pathophysiological processes, multi-biomarker panels and their relation to congestion and risks for progression of HF which can help to further refine biomarker-guided therapy.

Summary

This review evaluates the potential use of biomarkers in guided therapy for HF and explores the rationale for their integration into multimodal monitoring frameworks aiming for a more personalized and dynamic model of HF care, in which different monitoring approaches can reinforce each other.